Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients

2021 ◽  
Author(s):  
Khalid S. Hassanien ◽  
El‐Sayed M. El‐Sayed ◽  
Raed S. Ismail ◽  
Zakarya M. Zakarya ◽  
Gouda K. Helal
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Genotype 4 ◽  
Interleukin 28B ◽  
Egyptian Patients

scholarly journals Predictor factors of sustained virological response in patients with chronic hepatitis C treated with current direct-acting antiviral drugs

2020 ◽  
Vol 19 (9) ◽  
pp. 2015-2020
Author(s):  
Elwy M.K. Soliman ◽  
Hisham A.A. Morsy ◽  
Ashraf M.M. Othman ◽  
Ahmed M. Mady
Keyword(s):  
Chronic Hepatitis ◽  
Platelet Count ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Genotype 4 ◽  
Lower Baseline ◽  
Egyptian Patients ◽  
Cirrhotic Group

Purpose: To assess the efficacy and predictors of treatment response of chronic hepatitis C genotype 4 Egyptian patients with sofosbuvir and daclatasvir, with or without ribavirin.Methods: This prospective study enrolled 200 patients with chronic hepatitis C virus (HCV) genotype 4 infection who received sofosbuvir plus daclatasvir for 12 weeks, with the addition of ribavirin for treating cirrhotic patients. Immunological parameters such as natural killer (NK) cell percentage, phenotype, and serum C-X-C motif chemokine 10 (CXCL10) were evaluated prior to treatment and at the end of the treatment.Results: Overall, 92.5 % of the patients achieved sustained virological response at 12 weeks (SVR12), where the non-cirrhotic group had 96.29 % SVR12, while the cirrhotic group had 84.61 % SVR12. Nonresponders had lower pretreatment platelet count, higher CXCL10 levels, and lower baseline frequencies of NK cells and NK subgroup CD56- CD16+.Conclusion: Based on these results, the use of sofosbuvir plus daclatasvir with or without ribavirin for 12 weeks, is an effective regimen in the treatment of Egyptian patients infected with genotype 4 HCV. The predictors of non-response are advanced age, liver cirrhosis, lower pretreatment platelet count, higher level of CXCL10, lower baseline NK cells frequency and percentage of the dysfunctional subset CD56- CD16+. Keywords: Hepatitis C virus, Genotype 4, Sofosbuvir, Daclatasvir, Sustained virological response

Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C

2008 ◽  
Vol 28 (8) ◽  
pp. 1112-1119 ◽  
Author(s):  
Rita Raafat Gad ◽  
Sylvia Males ◽  
Hesham El Makhzangy ◽  
Soheir Shouman ◽  
Aboubakr Hasan ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Genotype 4

scholarly journals Predictors of Complete Early Virological Response to Pegylated Interferon and Ribavirin in Egyptian Patients with Chronic Hepatitis C Genotype 4

2013 ◽  
Vol 03 (02) ◽  
pp. 78-83 ◽  
Author(s):  
Gamal El Din Esmat Gamil ◽  
Maissa El Said El Raziky ◽  
Rabab Maamoun Salama ◽  
Wafaa Ahmed El Akel ◽  
Waleed Fouad Fathalah ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Pegylated Interferon ◽  
Early Virological Response ◽  
Genotype 4 ◽  
Egyptian Patients
Sign in / Sign up

Export Citation Format

Share Document